Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 490 (TSX: $DN.TO) (OTCQX: $VRNDF) (NASDAQ: $GWPH) (NASDAQ: $VFF) (TSX: $VFF.TO)
Today's podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland
Delta, Kelowna, BC, November 3, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/11031DN-VRNDF-GWPH-VFF.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
In today’s podcast we look at a few public and private company announcements.
Pure Extracts Technologies Corp., a plant-based extraction company focused on cannabis, hemp, and functional mushroom sectors, announced that the company’s stock will commence trading on the Canadian Securities Exchange (“CSE”) under the symbol “PULL” on November 5, 2020.
“There currently is a tremendous consumer demand for natural health products with the ability to immediately enhance our quality of life. With Health Canada officially granting Pure Extracts a Standard Processing License under the Cannabis Act, this has put us on a path to deliver full-spectrum oil products by the end of Q4, 2020” said chief executive officer Ben Nikolaevsky. “Our trading debut on the CSE is another vote of confidence in our ability to effectively meet the needs of consumers focused on receiving cannabis, hemp and functional mushroom products.”
Pure Extracts would like to thank its expert tradespeople who worked tirelessly on the its state-of-the-art facility in Pemberton, BC, its team of dedicated employees, and the investors who have financed the company for a total $9.45MM CAD allowing it to become a world-class, plant-based extraction company.
Pure Extracts was incorporated under the BCBCA and has its offices and operations in Pemberton, British Columbia. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act. Pure Extracts is undertaking the operations of toll processing, white labelling, and developing its own private label of products incorporating its full spectrum THC and CBD based extracted oils.
Additionally, Pure Extracts is presently expanding its business to include functional mushrooms extraction by working on functional mushroom extraction processes compatible with its existing infrastructure. Pure Extracts has a fully built CO2 extraction facility built to European Union GMP standards and intends to seek EU GMP certification of its operations allowing it to export its products for sale in Europe where such products are legal.
DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) announced that it has now surpassed one million transactions through its retail cannabis stores since legalization of recreational cannabis use. The Company opened its first “Delta 9 Cannabis Store” on October 17, 2018 and has since grown its retail store footprint to seven operating stores in the Manitoba and Alberta markets.
In addition to achieving the milestone number of transactions, the Company is pleased to provide the following statistics in connection with its retail cannabis business;
● Over 1,000,000 in-store and online transactions
● Over $50 Million in-store and online retail revenues
● Average transaction size of $50.20 per transaction
● Over 1.5 Million unique website visitors to delta9.ca
● Over 17,000 square feet of retail store space averaging $2,021 in revenue per square foot per year.
● Average Gross Profit margin of approximately 26%
"We are very pleased with the revenue growth generated from our retail stores since legalization in 2018," said John Arbuthnot, CEO of Delta 9. “Delta 9 has stayed focused on its strategy to vertically integrate into the retail segment and leveraging its retail business as a means to facilitate distribution of Delta 9 branded products directly to Canadian consumers.”
Management believes that there are a number of benefits to pursuing a vertical integration strategy into retail sales including:
● Control over a direct to consumer sales force and product distribution;
● Control over direct to consumer branding and marketing initiatives;
● Capturing additional revenues and gross margin from retail sales; and
● Direct feedback from consumers regarding product trends, marketing strategies, etc.
GW Pharmaceuticals plc (NASDAQ: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity.
Nabiximols, known as Sativex® outside of the U.S. and approved for use to treat MS spasticity in over 25 countries, is a complex botanical medicine formulated from extracts of the cannabis plant administered as an oral spray. Positive results from three previous European Phase 3 clinical studies show nabiximols was well-tolerated and provided continued reductions in patient-reported spasticity for individuals with MS.
This Phase 3 trial is one of five pivotal studies planned for nabiximols in MS spasticity, with the remaining studies on track to commence either later this year or in 2021. GW expects that a positive result in any one of these five studies will enable an NDA submission, potentially as early as mid- next year.
“We are excited that the U.S. Phase 3 clinical program evaluating nabiximols in Multiple Sclerosis spasticity is now recruiting patients, after a delay due to COVID-19. Given the rigorous studies already conducted on the medicine outside of the U.S., and positive discussions with the FDA, we believe that we have a clear path to an NDA submission, potentially as soon as next year, and a significant second product opportunity for GW in the U.S.,” stated Justin Gover, GW’s Chief Executive Officer. “Now is the ideal time to develop nabiximols in the U.S. as research shows a significant percentage of spasticity patients are today self-medicating using unapproved cannabis products to relieve their spasticity.”
“There is a significant need for new treatments to address spasticity in MS patients, a challenging condition with little therapeutic innovation in decades in the United States,” said Dr. Stephen Krieger, Associate Professor of Neurology at the Mount Sinai Hospital.
“Nabiximols has the potential to be a rigorously tested and FDA-regulated cannabis-derived medicine for people living with MS. I look forward to participating as an investigator in this study which will evaluate the effect of nabiximols on the frequency of muscle spasms.”
The study is a Phase 3, double-blind, parallel, placebo-controlled study that will evaluate the safety and efficacy of nabiximols for spasm frequency over a 12-week period and is expected to enroll 446 participants. The first patient is now screened and in baseline evaluation.
Beyond this initial study, the Company intends to commence the following additional Phase 3 trials of nabiximols for MS-associated spasticity:
● Phase 3 muscle tone studies – placebo-controlled cross-over design
○ N=52; Expected start: Q4 2020 (subject to COVID)
○ N=190; Expected start: Q1 2021
○ N=36 (nabiximols responders); Expected start: Q1 2021
● Phase 3 spasm frequency studies – placebo-controlled parallel group
○ N=~200 (nabiximols responders); Expected start: Q2 2021
Village Farms International, Inc. (NASDAQ: VFF) (TSX: VFF) announced it has completed the acquisition from Emerald Health Therapeutics, Inc. of 36,958,500 common shares of Pure Sunfarms Corp. owned by Emerald, representing approximately 41.3% of the issued and outstanding common shares of Pure Sunfarms. With the completion of the Pure Sunfarms Transaction, Village Farms now owns 100% of the common shares of Pure Sunfarms. The acquisition of the Pure Sunfarms shares will be immediately accretive to Village Farms' net income.
"Village Farms conceived of a joint venture to launch its Canadian cannabis business, and the result, Pure Sunfarms, is now one of the leading Canadian cannabis companies. With this transaction our shareholders will now fully benefit from our initiative," said Michael DeGiglio, CEO, Village Farms. "Pure Sunfarms is well positioned for long-term growth as one of what we believe will be just a small number of major suppliers to the Canadian cannabis market. Importantly, as part of the Village Farms organization Pure Sunfarms can now pursue additional opportunities to further leverage its success to date and increase its earnings potential. I am pleased to welcome the outstanding management team and employees of Pure Sunfarms to our organization, and welcome back so many Village Farms' personnel who transitioned to our cannabis venture in the early days to ensure that Pure Sunfarms would benefit fully from Village Farms' decades of experience and site-specific operational expertise. Pure Sunfarms' CEO, Mandesh Dosanjh, and his entire team have done exceptional work in bringing Village Farms' vision to reality, and we look forward to their continued contribution to its success as part of Village Farms going forward."
"The acquisition of the entirety of Pure Sunfarms is a defining moment for Village Farms, furthering our transformation to a vertically integrated, plant-based consumer packaged goods company. It allows us to fully leverage the invaluable cannabis expertise Village Farms has gained in combination with the organizational strength underlying the Village Farms produce business to pursue high-growth opportunities in emerging legal cannabis and CBD markets in the United States and targeted markets internationally. We will do so with the same thoughtfulness, prudence, strategic decision making and focus on near-term profitability and long-term return on invested capital that has been fundamental to the success of our investment in Pure Sunfarms."
"We especially look forward to the potential for U.S. regulatory changes that would permit us to pursue our U.S. cannabis aspirations. With one of the largest greenhouse footprints in the U.S., located in one of the best regions for growing in the country, alongside our cannabis success in Canada, we believe there is no company better positioned for long-term success in the U.S. cannabis industry. We are ready to move quickly and aggressively as soon as the regulatory environment permits."
Upon closing of the Pure Sunfarms Transaction, Pure Sunfarms will be fully consolidated in Village Farms' financial results. Village Farms will report its third quarter financial results and the third quarter financial results of Pure Sunfarms on November 13, 2020. Village Farms' financial results for the three and nine months ended September 30, 2020 will continue to reflect Village Farms' 58.7% ownership of Pure Sunfarms as an investment in a joint venture.
Once again, today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
800 665 0411